EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Political Pressure on Drug Pricing: Novo Nordisk faces increasing scrutiny over the high prices of its weight-loss drugs, Ozempic and Wegovy, in the U.S. compared to international markets, prompting CEO Lars Fruergaard Jorgensen to testify before Congress about the role of pharmacy benefit managers (PBMs) in drug pricing.
Market Stability Despite Price Cuts: Despite potential political pressure for price reductions, experts believe that Novo Nordisk's revenue will remain stable due to strong demand for its products, and anticipate increased M&A activity in the pharmaceutical sector post-election.
Analyst Views on HRTS
Wall Street analysts forecast HRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRTS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 36.475
Low
Averages
High
Current: 36.475
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
